JAMA Oncology

OCT 22, 2026 · JOURNAL ARTICLE

Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer

JAMA Oncology

Importance The I-SPY2.2 trial tests personalized treatment strategies to improve outcomes while reducing exposure to standard chemotherapy in patients with high-risk early breast c

OCT 15, 2026 · JOURNAL ARTICLE

Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma

JAMA Oncology

Importance Renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus is associated with substantial perioperative risk and frequent recurrence despite nephrectomy and

OCT 15, 2026 · JOURNAL ARTICLE

Nivolumab-Ipilimumab for Localized Microsatellite Instability–High Gastric/Gastroesophageal Junction Adenocarcinoma

JAMA Oncology

Importance Neoadjuvant nivolumab plus ipilimumab in localized deficient mismatch repair/microsatellite instability–high gastric or gastroesophageal junction (GEJ) adenocarcinoma wa

OCT 8, 2026 · JOURNAL ARTICLE

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2 -Positive, Non–Muscle-Invasive Bladder Cancer

JAMA Oncology

Importance Very high-risk non–muscle-invasive bladder cancer (VHR NMIBC) includes extensive high-grade T1 (T1HG) disease, T1HG with carcinoma in situ, variant histology, lymphovasc

OCT 1, 2026 · JOURNAL ARTICLE

Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer

JAMA Oncology

Importance Despite the integration of bevacizumab and poly(ADP-ribose) polymerase inhibitors into first-line treatment of advanced high-grade serous ovarian cancer, survival remain

SEP 24, 2026 · JOURNAL ARTICLE

Chemotherapy and Surgical Outcomes for Ovarian Metastases From Colorectal Cancer

JAMA Oncology

Importance Colorectal cancer is the third most common and deadly cancer among women worldwide. Although ovarian metastases from colon cancer are relatively uncommon, they remain cl

SEP 24, 2026 · JOURNAL ARTICLE

Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer

JAMA Oncology

This nonrandomized clinical trial assesses the utility of patient education materials and feasibility of longitudinal assessment of financial toxicity, quality of life, and out-of-

SEP 10, 2026 · JOURNAL ARTICLE

Modernizing Surrogate Decision-Making to Reflect the Complexity of Cancer Care

JAMA Oncology

This is a viewpoint piece proposing a framework for surrogate decision-making in cancer care; it presents expert perspective and normative guidance rather than empirical evidence of efficacy or outcomes.